What is the current status of the patent litigation for Exparel (paclitaxel injection) involving Evenus?
As of the provided information, the patent litigation concerning Exparel's U.S. Patent No. 9,495,463, involving Pacira Pharmaceuticals (now Pacira BioSciences) and Evenus, is active. The patent is set to expire in 2025 [1]. Evenus has filed an Abbreviated New Drug Application (ANDA) for a generic version of Exparel, which initiated the patent dispute under the Hatch-Waxman Act [1].
What are the key patents for Exparel?
The primary patent in question is U.S. Patent No. 9,495,463, which is listed in the FDA’s Orange Book for Exparel [1]. This patent covers aspects of the drug's formulation and method of use.
When does Exparel's U.S. Patent No. 9,495,463 expire?
U.S. Patent No. 9,495,463 is scheduled to expire in 2025 [1].
Why is Evenus challenging the patent for Exparel?
Evenus is challenging the Exparel patent as part of its efforts to gain U.S. Food and Drug Administration (FDA) approval for its generic version of the drug. By challenging the patent's validity or asserting non-infringement, Evenus aims to clear the way for its generic product's market entry [1].
What is Exparel and what is it used for?
Exparel (paclitaxel injection) is a long-acting local anesthetic approved for postoperative pain management [1]. It is administered by a healthcare professional during surgery to numb the area where the surgery was performed.
How does Exparel work?
Exparel utilizes proprietary liposomal encapsulation technology to deliver the local anesthetic agent, bupivacaine, directly to the site of the surgical incision. This formulation allows for sustained release of the medication, providing pain relief for an extended period, often lasting for days following surgery [1].
What is the significance of patent litigation for generic drug entry?
Patent litigation plays a critical role in the U.S. pharmaceutical market, particularly under the Hatch-Waxman Act. When a generic manufacturer files an ANDA, it often triggers a process where the brand-name manufacturer can sue for patent infringement. This litigation can delay the entry of generic alternatives, potentially extending the period of market exclusivity for the brand-name drug [1].
What is an Abbreviated New Drug Application (ANDA)?
An ANDA is the pathway for generic drug manufacturers to seek FDA approval to market a generic version of an approved brand-name drug. It demonstrates that the generic drug is bioequivalent to the reference listed drug [1].
What are the potential impacts of generic Exparel entry?
The entry of generic Exparel could lead to a significant reduction in the cost of postoperative pain management. This would likely benefit healthcare providers and patients by increasing access to effective pain relief [1].
Where can I find more information on drug patents and litigation?
Information on drug patents, their expiration dates, and ongoing litigation can be found on resources like DrugPatentWatch.com [1].
---
1. DrugPatentWatch.com.